Director Dealings

Verona Pharma plc ("Verona Pharma" or the "Company") Director's Dealing 5 December 2014, Cardiff, UK - Verona Pharma plc (AIM: VRP.L) (the "Company")received notification on 4 December 2014 that on that date, Mr StuartBottomley, a non-executive director of the Company, acquired via his SIPP aninterest in 250,000 ordinary shares of 0.1p each in the Company ("OrdinaryShares") at a price of 1.21 pence per share. Following the acquisition, Mr. Bottomley will have an interest in the Companyof 19,000,000 Ordinary Shares, representing 1.88% of the Company's issuedordinary share capital. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0)20 7863 3300Jan-Anders Karlsson, CEO N+1 Singer Tel: +44 (0)20 7496 3000Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma plc is a UK-based clinical stage biopharmaceutical companyfocused on the development of innovative prescription medicines to treatrespiratory diseases with significant unmet medical needs, such as COPD, asthmaand cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-classdrug currently in Phase II trials as a nebulised treatment for acuteexacerbations of COPD in the hospital setting. The drug is a dualphosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator andanti-inflammatory effects, which are essential to the improvement of patientswith COPD and asthma. Verona Pharma is also building a broader franchise aroundRPL554 to maximise its value, both to patients and to investors. This includesthe very significant markets for COPD and asthma maintenance therapy. TheCompany is also exploring the potential of the drug in different diseases, suchas cystic fibrosis, where it is in pre-clinical testing.